IGF::OT::IGF IDENTIFICATION OF ANTI-HIV LEAD COMPOUNDS

开发和采用新的艾滋病毒疗法和局部杀微生物剂仍然是公共卫生的一个高度优先事项。为了帮助填补这些公共卫生空白，NIAID支持来自学术界，私营部门或其他来源的有前途的治疗和局部杀微生物剂候选物的临床前开发。该合同提供产品开发服务，利用生化和基于细胞的检测，包括标准和高通量筛选（HTS）形式。根据本合同提供的服务将帮助各种研究人员获得获得额外资金所需的关键数据，获得潜在的合作伙伴关系（用于进一步开发或支持I期试验），并满足监管机构对研究性新药（IND）申请的要求。 将开展优化、开发和合成先导化合物和类似物的活动。

The development and introduction of new therapeutics and topical microbicides against HIV remains a high public health priority. To assist in filling these public health gaps, the NIAID supports preclinical development of promising therapeutic and topical microbicide candidates that emerge from academia, the private sector, or other sources. This contract provides product development services utilizing biochemical and cell-based assays in both standard and high throughput screening (HTS) formats. The services provided under this contract will assist a wide variety of investigators in obtaining critical data needed to acquire additional funding, gain prospective partnerships (either for further development or to support Phase I trials), and fulfill regulatory agency requirements for investigational new drug (IND) applications. Activities to optimize, develop, and synthesize lead compounds and analogs will be undertaken.